Cartalax (AED Peptide)

Proposed to normalize bone and cartilage metabolism via modulation of chondrocyte gene expression (SOX9, aggrecan, type II collagen, COMP) and aging markers (SIRT1, SIRT6, Ki-67, p53).

No validated clinical use. Russian dietary supplement. Evidence insufficient for therapeutic recommendation.

No modern clinical PK or registered RCT. Formulation in patent (IM) differs from commercial products (oral/lingual) — not equivalent evidence objects.

Single unregistered human study (patent example): 54.5-62.7% pain/mobility improvement in knee OA (n=29, no p-values). Multiple preclinical cartilage studies from Khavinson group.

• 1.RU2299741C1 Patent Example 5 — knee OA: pain/mobility improvement 54.5-62.7% at IM doses 1mcg-5mg/day x 20 days. No radiographic improvement. No p-values, no AE table. n=29 (human, patent, unregistered)
• 2.AED in aging MSC chondrogenesis 2022 — activated SOX9, aggrecan, type II collagen, COMP at 200 ng/mL (preclinical)
• 3.Myakisheva et al., Vrach 2023 — chondrocyte proliferation: 1.4-2.1x at 200 ng/mL in young/old cultures (preclinical)
• 4.Fridman et al., 2020 — increased SIRT1, SIRT6, collagen I in aging fibroblasts (preclinical)

Single difficult-to-audit patent narrative with no p-values, no AE table, no registry. No Phase III or FDA/EMA approval.